Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Omnicell, Inc.
OMCL
NASDAQ·Healthcare·Information Technology Services·Mkt cap $1.9B
$43.03
▲ +2.62%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$26.85 - $55.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 40.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive integrated platform spanning point-of-care to central pharmacy automation
- Proprietary robotic and automation technology with significant switching costs
- Deep healthcare system relationships and established market presence since 1992
- Software ecosystem creating recurring revenue and customer lock-in through interface integration
Bear Case
2 risks
- Average volatility.
- Premium valuation to Healthcare IT & Services peers
Growth
Stable outlook
Increasing hospital demand for medication automation to address nursing shortages and improve safety
Value
Premium valuation to Healthcare IT & Services peers
Momentum
Hot
+22.8% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying OMCL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 30, 2026
APR 28, 2026
Reported EPS of $0.55 vs $0.33 consensus (+66.7% surprise). Revenue of $309.9M vs $304.0M expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+66.7%
Next: Jul 30, 2026
Revenue trend · last 8Q
—
—
+19%
+10%
+5%
+10%
+2%
+15%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$276.8M
$282.4M
$306.9M
$269.7M
$290.6M
$310.6M
$314.0M
$309.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
3.7%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$70.00
▲ +62.7% vs $43.03
Latest: Craig-Hallum · $55.00 · Apr 29, 2026
2 analysts covering